Welcome to our dedicated page for Landos Biopharma news (Ticker: LABP), a resource for investors and traders seeking the latest updates and insights on Landos Biopharma stock.
Landos Biopharma, Inc. (LABP) is a clinical-stage biotechnology company pioneering oral therapies for autoimmune diseases through innovative immunometabolic research. This page provides centralized access to official news and developments surrounding LABP's scientific advancements, clinical trials, and corporate milestones.
Investors and stakeholders will find timely updates on LABP's lead investigational drug NX-13, including Phase 2 trial progress for ulcerative colitis treatment. The curated news archive features regulatory filings, partnership announcements, and financial reports essential for informed decision-making.
Our coverage spans key developments including clinical trial outcomes, research collaborations, and strategic corporate actions. All content is verified through primary sources to ensure accuracy in reporting scientific data and business developments.
Bookmark this page for direct access to LABP's latest advancements in inflammatory bowel disease research and emerging treatment paradigms. Check regularly for updates on novel oral therapies that aim to transform autoimmune disease management.
AbbVie has completed its acquisition of Landos Biopharma, enhancing its portfolio with NX-13, a first-in-class oral NLRX1 agonist currently in Phase 2 trials for treating ulcerative colitis (UC) and Crohn's disease (CD). The acquisition, priced at $20.42 per share plus up to $11.14 per share upon achieving a clinical milestone, aims to offer a novel, dual-action treatment approach to inflammatory bowel disease (IBD), combining anti-inflammatory properties and epithelial repair. Landos' stock will stop trading on NASDAQ from May 24, 2024. AbbVie expressed its commitment to transforming the standard of care for IBD patients.
